Anti-CLL1 CAR-T cell therapy in pediatric R/R AML

1 Views

07/14/23

Rayne H Rouce, MD, Baylor College of Medicine, Houston, TX & Texas Children's Hospital, Houston, TX, provides a summary of the Phase I trial (ChiCTR1900027684) of an anti-CLL1 2nd generation chimeric antigen receptor (CAR) T-cell therapy in pediatric patients with relapsed/refractory acute myeloid leukemia (AML). Whilst CAR T-cell therapy has been successful in treating B-cell malignancies, CAR T-cell-based leukemia treatment in AML are limited due to disease heterogeneity. In a cohort of 11 patients, 10 completely responded to treatment, demonstrating efficacy and safety. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.